Comparing the current results to its competitors, Euda Health Holdings Limited reported Revenue increase in the 4 quarter 2025 by 59.29 % year on year. The sales growth was above Euda Health Holdings Limited's competitors' average revenue growth of 53.05 %, achieved in the same quarter.
Euda Health Holdings Limited, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 135.38 %
Due to outstanding performance in Overall company, revenue grew by 59.29 % Euda Health Holdings Limited improved its market share, to approximately 0.02 %.
Publicly Traded Peers of Euda Health Holdings Limited
Qhslab Inc Share Performance
+33.33%
Over The Past 5 Days
Qhslab Inc
Profile
Qhslab Inc is a technology-based company that operates on a subscription-based business model, offering software solutions for data analytics and processing. Their services cater to various industries, providing clients with tools to efficiently analyze and utilize their data. Qhslab Inc generates revenue by charging a recurring fee for access to their software platform, which is regularly updated to meet the evolving needs of their customers.
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Sources:
Euda Health Holdings Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Euda Health Holdings Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
